Clinical trial · Observational
Perioperative Management of Preoperative Anemia in Colorectal Cancer
Perioperative Management of Preoperative Anemia in Colorectal Cancer. Effect of Intravenous Iron Treatment Within a Patient Blood Management on Colorectal Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Both preoperative anemia (PA) and perioperative blood transfusion can contribute on poorer outcomes after colon cancer surgery. Anemia is known to be associated with a slower recovery after surgery thus often worsening short-term results, and allogenic red blood cells transfusion (ARBT) are known to promote systemic inflammatory response and affect overall and cancer-specific survival. Patient Blood Management (PBM) systems are an evidence-based multimodal approach focused on safe and rational use of blood products, mainly through a proper PA assessment, a minimization of procedural blood loos and strict transfusion policies. Given the high prevalence of PA in patients with colorectal cancer (CRC), and its association with adverse events, it is expected that PBM implementation in said scenario carries a decrease in complications and an improved survival rate. Available literature to date supports preoperative anaemia screening and restrictive transfusion policies, nevertheless barriers exist that limit the expected implementation of PBM systems in colorectal surgery. The present study aims to evaluate feasibility of a PBM pathway implementation in a high-volume CRC Surgery Unit based on completion of anemia screening and treatment before surgery and changes of allogenic products use along the years. The objective is to estimate the impact of a proper preoperative optimization with iron intravenous infusion (IVI) on PA measured from changes Hemoglobin (Hb) levels in comparison to those of non-anemic patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- cohort 1
- description
- non-anemic patients (Hb \> 13 g/dL)
- label
- cohort 2
- description
- mildly anemic patients (Hb 12-13 mg/dL) without criteria for IVI therapy
- label
- cohort 3
- description
- patients treated with IVI (Hb \< 12mg/dL or Hb 12-13mg/dL with iron deficiency or risk factors for bleeding)
Primary outcomes (1)
- measure
- Change in Hemoglobin
- timeFrame
- Baseline and up to 30 days
- description
- Change in serum hemoglobin concentration between baseline (at the moment of initial colorectal clinic visit) and day of surgery
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with Colorectal Cancer * Patients with an indication of elective radical surgery Exclusion Criteria: * treatment with red blood cells transfusion before assessment in the PBM Anemia Clinic * non-iron deficient anemia * treatment with Sucrose-based IVI or Oral Iron (OI) preparations not strictly controlled by the PBM clinic
References
Publications (0)
Data not yet available